Leonard F Liebes

Summary

Affiliation: New York University
Country: USA

Publications

  1. pmc The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
    Michael T Buckley
    Urology, New York University School of Medicine, New York, USA
    J Transl Med 5:49. 2007
  2. ncbi request reprint High-performance liquid chromatography-based determination of total isothiocyanate levels in human plasma: application to studies with 2-phenethyl isothiocyanate
    L Liebes
    Division of Oncology, Department of Medicine, New York University Medical Center, New York, New York 10016, USA
    Anal Biochem 291:279-89. 2001
  3. ncbi request reprint Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group
    H Hochster
    Kaplan Cancer Center and New York University Medical Center, New York, and Albert Einstein College of Medicine, Bronx, NY, USA
    J Clin Oncol 17:2553-61. 1999
  4. ncbi request reprint Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle
    A L Hamilton
    New York University School of Medicine, New York, NY, USA
    J Clin Oncol 23:6107-16. 2005

Collaborators

Detail Information

Publications4

  1. pmc The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
    Michael T Buckley
    Urology, New York University School of Medicine, New York, USA
    J Transl Med 5:49. 2007
    ....
  2. ncbi request reprint High-performance liquid chromatography-based determination of total isothiocyanate levels in human plasma: application to studies with 2-phenethyl isothiocyanate
    L Liebes
    Division of Oncology, Department of Medicine, New York University Medical Center, New York, New York 10016, USA
    Anal Biochem 291:279-89. 2001
    ..The applicability of the methodology to pharmacokinetic studies of PEITC in humans is demonstrated...
  3. ncbi request reprint Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group
    H Hochster
    Kaplan Cancer Center and New York University Medical Center, New York, and Albert Einstein College of Medicine, Bronx, NY, USA
    J Clin Oncol 17:2553-61. 1999
    ....
  4. ncbi request reprint Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle
    A L Hamilton
    New York University School of Medicine, New York, NY, USA
    J Clin Oncol 23:6107-16. 2005
    ..We performed a phase I study of a day (D) 1 and D4 bortezomib administration once every 2 weeks to determine the recommended phase II dose and toxicity profile, and the extent of 20S proteasome inhibition obtained...